Fixed-dose rate gemcitabine plus carboplatin in relapsed, platinum-sensitive ovarian cancer patients: Results of a three-arm Phase I study

FDR gemcitabine + carboplatin on a 21-day schedule was active and produced no unusual safety signals in patients with Pt-S OC.